| Autor: |
Seelman, Sharon L., Bazaco, Michael C., Wellman, Allison, Hardy, Cerisé, Fatica, Marianne K., Huang, Mei-Chiung Jo, Brown, Anna-Marie, Garner, Kimberly, Yang, William C., Norris, Carla, Moulton-Meissner, Heather, Paoline, Julie, Bicking Kinsey, Cara, Kim, Janice J., Kim, Moon, Terashita, Dawn, Mehr, Jason, Crosby, Alvin J., Viazis, Stelios, Crist, Matthew B. |
| Zdroj: |
Epidemiology & Infection; 2022, Vol. 150, p1-8, 8p |
| Abstrakt: |
In March 2018, the US Food and Drug Administration (FDA), US Centers for Disease Control and Prevention, California Department of Public Health, Los Angeles County Department of Public Health and Pennsylvania Department of Health initiated an investigation of an outbreak of Burkholderia cepacia complex (Bcc) infections. Sixty infections were identified in California, New Jersey, Pennsylvania, Maine, Nevada and Ohio. The infections were linked to a no-rinse cleansing foam product (NRCFP), produced by Manufacturer A, used for skin care of patients in healthcare settings. FDA inspected Manufacturer A's production facility (manufacturing site of over-the-counter drugs and cosmetics), reviewed production records and collected product and environmental samples for analysis. FDA's inspection found poor manufacturing practices. Analysis by pulsed-field gel electrophoresis confirmed a match between NRCFP samples and clinical isolates. Manufacturer A conducted extensive recalls, FDA issued a warning letter citing the manufacturer's inadequate manufacturing practices, and federal, state and local partners issued public communications to advise patients, pharmacies, other healthcare providers and healthcare facilities to stop using the recalled NRCFP. This investigation highlighted the importance of following appropriate manufacturing practices to minimize microbial contamination of cosmetic products, especially if intended for use in healthcare settings. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
